Latest news with #Alzheimer's-related
Yahoo
17 hours ago
- Health
- Yahoo
3 Foods To Buy Every Week To Lower Your Dementia Risk, According to Registered Dietitians
3 Foods To Buy Every Week To Lower Your Dementia Risk, According to Registered Dietitians originally appeared on Parade. Everything we consume impacts the body for better or for worse, including the brain. Fortunately, there are literally hundreds, if not thousands, of foods that are beneficial for brain health. Many of these foods are part of the MIND diet, which stands for Mediterranean-DASH Intervention for Neurodegenerative MIND diet was created with dementia prevention in mind. While it's certainly a positive that the MIND diet, and eating for brain health generally, includes so many foods, it's also helpful to have a starting point. After all, the longest-lasting dietary changes are typically made in increments, not all at once. With this in, er, mind, we asked registered dietitians which three foods they recommend people start integrating into their diet to support brain health because they are so impactful. 🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊 General Tips for Lowering Dementia Risk Through Diet 'What we eat is one very important tool in our toolbox when it comes to reducing the risk of dementia,' says Laura Ali, RD, a registered dietitian and culinary nutritionist. As evidence, Ali highlights a scientific study showing that following the MIND diet has been shown to cut dementia risk in dietitian and In Good Health president Serena Benali, RD, agrees that food can be a powerful tool in dementia prevention. 'Although we cannot alter our genes or age, we can reduce inflammation and oxidative stress, support vascular health and maintain metabolic balance through our food choices, which lowers the risk of dementia,' she says. Related: 'Brain autopsy research from the National Institute on Aging also showed that older adults who ate these dietary patterns consistently had fewer Alzheimer's-related changes, even into their 90s,' Benali maintaining a brain-healthy diet is not a guarantee that you won't get Alzheimer's, Benali emphasizes that it's one of the most powerful tools there is, especially when combined with regular physical activity, meaningful social connection and effective stress management. Related: In terms of some general tips for lowering dementia risk through diet, Ali says to prioritize vegetables and fruit as well as foods with brain-healthy omega-3s, such as seafood, nuts, seeds, eggs and edamame. Benali says that keeping blood glucose in a healthy, stable range during midlife is linked to a lower risk of dementia later on, according to scientific research. 'Practical strategies include building each meal around fiber-rich carbohydrates, lean protein and healthy fats, spacing meals at regular intervals to avoid sharp spikes and crashes and limiting highly processed foods that are often high in refined starches and added sugars,' she 3 Foods To Buy Every Week To Lower Your Risk of Dementia With all this in mind, what foods do the dietitians recommend starting with when integrating more brain-supporting foods into your diet? Below are the three they say make the most impact. 1. Berries Satisfy your cravings for sweets while lowering your dementia risk by snacking on berries. 'Berries are rich in flavonoids, a compound found in plants that has antioxidant properties. The flavonoids are thought to protect the signaling pathways in the brain, which protects memory and the ability to perform daily activities. Research has shown that people who eat more berries have improved memory and better cognitive function,' Ali says, adding that she recommends eating them three to four times a also recommends eating berries regularly, explaining, 'Regular berry eaters have shown better memory and a slower rate of cognitive decline in several human studies." 2. Seafood 'All types of seafood, but especially those with higher amounts of omega-3 fatty acids like salmon, sardines, trout and tuna, are important to include at least once a week,' Ali says. Benali adds that eating sardines regularly can be especially beneficial, explaining, 'This cold-water fish is packed with DHA-rich omega-3 fats, the very lipids that make up our brain cell membranes. Adequate DHA helps brain cells communicate efficiently and may calm neuroinflammation. Because marine sources already contain DHA, they are more readily used by the body than plant-based ALA sources." According to Ali, people who eat seafood regularly have a lower risk of heart disease, and there is also evidence that the omega-3s may help reduce the formation of amyloid protein clusters in the brain. 'Those clusters block the flow of communication in your brain and contribute to the death of healthy brain cells, which leads to dementia,' she explains. 3. Leafy greens The beauty of leafy greens is that they can be integrated into countless meals; they're one of the most versatile brain-healthy foods you can buy. 'Leafy greens are one of the key foods found to help reduce the risk of dementia. A study in the Journal of Neurology found that people who ate more leafy green vegetables like kale, spinach and arugula had significantly less plaque buildup in their brains than those who ate less,' Ali says. While berries, seafood and leafy greens are great foods to start integrating into your diet if you want to lower your risk of dementia, Benali says that eating a variety of nutrient-rich foods is key. 'Aim for 30 or more different plant-based foods each week—yes, 30! Fruits, vegetables, legumes, whole grains, nuts, seeds and herbs all count. A diverse intake feeds a broader range of gut microbes, and emerging evidence shows that a richer gut microbiome is associated with better cognitive resilience. Simple ways to begin include rotating your produce, sprinkling mixed seeds and experimenting with new vegetables each week,' she says. By prioritizing foods that support brain health in your diet, you're taking a major step in preserving your memory both now and in the future. Don't underestimate the power of what you eat! Up Next: Sources Laura Ali, RD, registered dietitian and culinary nutritionist Serena Benali, RD, registered dietitian and In Good Health president 3 Foods To Buy Every Week To Lower Your Dementia Risk, According to Registered Dietitians first appeared on Parade on Jul 21, 2025 This story was originally reported by Parade on Jul 21, 2025, where it first appeared. Solve the daily Crossword
NBC News
21 hours ago
- Health
- NBC News
Could cancer drugs be the future of Alzheimer's treatment?
With few treatments available to stop or reverse Alzheimer's disease, scientists have turned to cancer drugs as a potential means of walking back cognitive decline. Alzheimer's cases are rising in the United States and worldwide due to an aging population, but there is no cure for the disease. Attempts to develop new treatments that slow the disease's progress, rather than lessen symptoms, have frequently failed. Only two drugs — the antibody therapies Leqembi and Kisunla — are currently approved by the Food and Drug Administration to slow the progression of early Alzheimer's, and scientists say their benefits are limited. Some pharmaceutical companies have halted or abandoned their Alzheimer's drug development programs because of unsuccessful trials. Others are trying to use existing medications, including popular weight loss drugs, to combat Alzheimer's. With that in mind, researchers at the University of California, San Francisco conducted a broad search for drugs that could be repurposed to treat the condition — in theory, reducing the time in which the drugs could be made available to patients. They scoured a database of more than 1,300 drugs of various classes, including antipsychotics, antibiotics, antifungals and chemotherapy drugs. Then, they looked at how those drugs affected gene expression. Their new study, published Monday in the journal Cell, identified two cancer drugs as the best candidates to lower Alzheimer's risk in patients. When combined, the drugs seemed to slow or reverse Alzheimer's symptoms in mice. One of the drugs is normally used to treat breast cancer, while the other is effective against colon and lung cancer. Alzheimer's disease is associated with significant changes in the way genes are expressed in the brain, leading to the increased production of certain proteins and the decreased production of others. These imbalances may disrupt brain function and contribute to symptoms like memory loss. Fewer than 90 drugs in the researchers' database reversed the expression of signature Alzheimer's-related genes in human brain cells. And five drugs in particular seemed to lower the risk of Alzheimer's in actual patients, based on electronic medical records. The authors ultimately selected two of those drugs, both approved by the FDA to treat cancer, to test in mice. 'We didn't expect cancer drugs to come up' as the most promising, said Marina Sirota, a co-author of the study and interim director of the UCSF Bakar Computational Health Sciences Institute. The authors said the breast cancer drug letrozole seemed to change gene expression in nerve cells. And the colon and lung cancer drug irinotecan seemed to change gene expression in glial cells, which support the nervous system. Alzheimer's can destroy nerve cells and cause glial cells to proliferate, creating inflammation in the brain. In a 2020 study, breast cancer patients who received letrozole were less likely to develop Alzheimer's than patients who did not receive the drug. Colorectal cancer survivors treated with irinotecan also had a decreased Alzheimer's risk, according to a 2021 study. After testing the drugs in mice, the study authors found that the two-drug combo reversed brain degeneration and improved memory in mice that had developed hallmarks of Alzheimer's as they aged. Because results in mice often don't translate to humans, the researchers hope to test the drugs in a clinical trial with Alzheimer's patients. 'Developing a new drug can take hundreds of millions, or even billions, of dollars, on average take more than 10 years. For this repurposed drug, usually it just takes two or three years, and then you can go to the clinical trial and the cost is much, much lower,' said Dr. Yadong Huang, a co-author of the study and professor of neurology at UCSF. 'We still haven't generated or produced any very effective drugs that can really slow dramatically the cognitive decline,' he added. Part of the difficulty in developing drugs for Alzheimer's is the complexity of the disease. Its exact cause is largely unknown. For now, the authors said, it's unclear exactly why the cancer drugs seem to work against Alzheimer's. One theory is that the breast cancer drug blocks the production of estrogen, a hormone that controls the expression of a large number of genes. The colon and lung cancer drug may also block inflammation in the brain by preventing the proliferation of glial cells — though Huang said there are other possibilities. Dr. Melanie McReynolds, an assistant professor of biochemistry at Pennsylvania State University, who was not involved in the study, offered another theory. Her research has suggested that a different type of cancer drug could help treat Alzheimer's by regulating glucose metabolism, the process by which cells make energy. McReynolds said the process is necessary for various brain cells to communicate with each other. 'With aging, with stress, with diseases, that line of communication is disrupted,' she said. McReynolds said the drug combo tested in the new study might reverse metabolic decline — what she called 'the secret for contributing to better outcomes with Alzheimer's.' But assessing how Alzheimer's patients tolerate the combination of cancer drugs will be important. Letrozole can cause hot flashes and irinotecan can cause severe diarrhea. Both drugs can lead to nausea and vomiting. 'These drugs have huge side effects, so you need to always balance and figure out whether those types of side effects would be amenable to somebody with Alzheimer's,' Sirota said. 'It's not that it's a slam dunk.'
Jordan News
a day ago
- Health
- Jordan News
Health Surprise: Eggs May Reduce Alzheimer's Risk in Seniors! - Jordan News
Health Surprise: Eggs May Reduce Alzheimer's Risk in Seniors! As the world continues to face the rising tide of Alzheimer's disease and age-related cognitive decline, researchers are increasingly exploring everyday lifestyle choices and dietary habits that could help protect against early mental deterioration. One such simple food—eggs—has come into the spotlight. A recent study published in the Journal of Nutrition, based on exclusive data from a research sample, suggests that eating more than one egg per week may significantly reduce the risk of Alzheimer's in older adults. اضافة اعلان What is Alzheimer's Disease? According to the National Institute on Aging, Alzheimer's is the most common form of dementia—a brain disorder that gradually destroys a person's memory and thinking skills. Symptoms include loss of cognitive functions such as reasoning, memory, and judgment. It's also common for individuals to have more than one type of dementia; for example, someone may have both Alzheimer's and vascular dementia. Inside the Study: Examining the Link Between Egg Consumption and Brain Health The study, titled 'Association Between Egg Consumption and Risk of Dementia and Alzheimer's Disease in Older Adults,' tracked more than 1,024 adults (average age: 81.4 years), all of whom were dementia-free at the beginning of the 7-year study. Their diets were evaluated using a validated food frequency questionnaire, and cognitive performance was assessed annually. By the end of the study, 280 participants had developed Alzheimer's-related dementia. However, those who consumed more than one egg per week were nearly 50% less likely to develop the disease compared to those who ate fewer eggs. Why Eggs? What Makes Them Brain-Friendly? A key factor highlighted in the research is choline—a vital nutrient found abundantly in eggs. Though not a vitamin, choline functions like one, playing a crucial role in supporting brain and body function. While the body produces a small amount of choline, the majority comes from food. In addition to brain health, choline helps reduce inflammation, regulate mood and mental health, support muscle function, and assist in fat metabolism. Other Dietary Sources of Choline Include: Eggs (especially the yolk) Fish (like salmon and tuna) Chicken or turkey Milk and other dairy products Risk of Alzheimer's and Neurological Diseases: Additional Findings Researchers also conducted autopsies on the brains of 578 deceased participants. The findings were striking: Reduced Amyloid Plaques – Protein build-ups strongly linked to Alzheimer's. Fewer Neurofibrillary Tangles – Twisted fibers inside brain cells that impair brain function and contribute to cognitive decline. What Did the Researchers Conclude? The results suggest that regular egg consumption is associated with a lower risk of dementia and Alzheimer's disease, with dietary choline playing a key role. As scientists continue to explore the impact of nutrition on brain health, studies like this underscore the powerful potential of simple, accessible dietary choices—like eating eggs—to support long-term cognitive well-being. Source: Times of India
Business Upturn
5 days ago
- Health
- Business Upturn
Dementia Associated with Alzheimer's Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers
By GlobeNewswire Published on July 17, 2025, 22:00 IST New York, USA, July 17, 2025 (GLOBE NEWSWIRE) — Dementia Associated with Alzheimer's Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsight Dementia associated with Alzheimer's disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population worldwide is leading to a rising prevalence of Alzheimer's-related dementia, fueling demand for effective diagnostics and disease-modifying therapies. DelveInsight's 'Dementia Associated with Alzheimer's Disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline dementia associated with Alzheimer's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the dementia associated with Alzheimer's disease pipeline domain. Key Takeaways from the Dementia Associated with Alzheimer's Disease Pipeline Report DelveInsight's dementia associated with Alzheimer's disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline dementia associated with Alzheimer's disease drugs. active players working to develop pipeline dementia associated with Alzheimer's disease drugs. Key dementia associated with Alzheimer's disease companies such as BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. , Merry Life Biomedical Company , Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others are evaluating new dementia associated with Alzheimer's disease drugs to improve the treatment landscape. and others are evaluating new dementia associated with Alzheimer's disease drugs to improve the treatment landscape. Promising pipeline dementia associated with Alzheimer's disease therapies, such as Bezisterim KarXT, CT-1812, TB 006, CM383, ALZ 101, AR1001, CT1812, ABBV-916, ALX-001, E2814, VT301, AMX0035, TML-6, PRX-P4-003, ADP037-ABC, GAL-201, MP-010, NVG 300, PSY-02, EMCBD-1, S-636, ADEL-Y07, TRx0237, Remternetug, Masupirdine, Masitinib, Piromelatine, MK-1167, Siponimod, PRI-002, PMZ-1620, Sargramostim, Bepranemab, Lomecel-B, and others, are in different phases of Dementia Associated with Alzheimer's Disease clinical trials. and others, are in different phases of Dementia Associated with Alzheimer's Disease clinical trials. In May 2025, Nuravax Inc. was awarded a USD 3 million grant from the National Institutes of Health (NIH) to support Duvax, the first dual-target Alzheimer's vaccine, in its entry into human clinical trials. was awarded a USD 3 million grant from the National Institutes of Health (NIH) to support Duvax, the first dual-target Alzheimer's vaccine, in its entry into human clinical trials. In February 2025, NKGen Biotech, Inc . announced that the US Food and Drug Administration had granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. . announced that the US Food and Drug Administration had granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. In February 2025, Swedish pharmaceutical company AlzeCure Pharma secured a Eur 2.5m (USD 2.62m) grant from the EU's European Innovation Council (EIC) to support a Phase IIa trial of NeuroRestore ACD856 for Alzheimer's disease. Swedish pharmaceutical company AlzeCure Pharma secured a Eur 2.5m (USD 2.62m) grant from the EU's European Innovation Council (EIC) to support a Phase IIa trial of NeuroRestore ACD856 for Alzheimer's disease. In April 2025, Biogen announced that the US Food and Drug Administration had granted Fast Track designation to BIIB080 , an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. announced that the US Food and Drug Administration had granted Fast Track designation to , an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. In March 2025, Longeveron Inc. announced the positive outcome of a Type B meeting with the US Food and Drug Administration, supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease. The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase II/III clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration, and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study. announced the positive outcome of a Type B meeting with the US Food and Drug Administration, supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease. The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase II/III clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration, and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study. In February 2025, Neuphoria Therapeutics announced that the company was due to receive a USD 15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment was triggered by the initiation, by Merck, of a Phase II clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia. announced that the company was due to receive a USD 15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment was triggered by the initiation, by Merck, of a Phase II clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia. In February 2025, NKGen Biotech announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of troculeucel , ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of , ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. In February 2025, NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it had received approval for its Phase II clinical trial from the European Medicines Agency (EMA). NTRX-07, the company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSA, and Trails Making Test), the trial is also designed to give an indication of target engagement by analyzing various biomarkers of neuroinflammation and neuronal function. a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it had received approval for its Phase II clinical trial from the European Medicines Agency (EMA). NTRX-07, the company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSA, and Trails Making Test), the trial is also designed to give an indication of target engagement by analyzing various biomarkers of neuroinflammation and neuronal function. In January 2025, the US FDA granted Fast Track designation to Posdinemab , a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease. the US FDA granted Fast Track designation to , a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease. In November 2024 , Alector announced results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). , announced results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). In October 2024, Hoth Therapeutics, Inc. announced the granting of a US patent for its pioneering Alzheimer's treatment, HT-ALZ. Request a sample and discover the recent advances in dementia associated with Alzheimer's disease drugs @ Dementia Associated with Alzheimer's Disease Pipeline Report The dementia associated with Alzheimer's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage dementia associated with Alzheimer's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the dementia associated with Alzheimer's disease clinical trial landscape. Dementia Associated with Alzheimer's Disease Overview Dementia is a broad term that refers to a marked decline in cognitive abilities that affects a person's daily functioning. Alzheimer's disease (AD) is the most common form of dementia, responsible for at least two-thirds of cases in people aged 65 and older. AD is a progressive neurodegenerative disorder that begins gradually and leads to worsening impairments in behavior and cognitive skills such as memory, understanding, language, attention, reasoning, and judgment. Although Alzheimer's itself is not directly fatal, it greatly increases the risk of other complications that can ultimately result in death. The diagnosis of Alzheimer's-related dementia usually requires a thorough evaluation, including medical history, cognitive assessments, physical and neurological exams, and sometimes brain imaging. Physicians first exclude other possible causes of cognitive decline, like vitamin deficiencies or thyroid issues. Cognitive tests evaluate memory, problem-solving, and language to identify patterns indicative of Alzheimer's. Brain scans, such as MRI or CT, help detect structural changes like brain shrinkage. More advanced diagnostic tools, including PET scans or cerebrospinal fluid tests, can reveal specific biomarkers linked to Alzheimer's, offering stronger confirmation. Currently, there is no cure for Alzheimer's disease since brain cell loss cannot be reversed. However, treatments are available to ease symptoms and enhance the quality of life for patients and their caregivers. Cholinesterase inhibitors are medications that help reduce cognitive symptoms such as memory problems, confusion, and impaired judgment by improving communication between brain cells and slowing symptom progression. The three FDA-approved drugs commonly used for Alzheimer's treatment include donepezil (Aricept) for all stages, and galantamine (Razadyne) and rivastigmine (Exelon) for mild to moderate stages. Find out more about dementia associated with Alzheimer's disease drugs @ Dementia Associated with Alzheimer's Disease Treatment A snapshot of the Pipeline Dementia Associated with Alzheimer's Disease Drugs mentioned in the report: Drugs Company Phase MoA RoA Bezisterim (NE3107) BioVie III NF-kappa B inhibitor; Tumour necrosis factor inhibitor Oral KarXT Bristol Myers Squibb III Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists Oral Buntanetap Annovis Bio III Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors Oral AR1001 AriBio III Type 5 cyclic nucleotide phosphodiesterase inhibitors Oral CT-1812 Cognition Therapeutics II Sigma-2 receptor antagonists Oral TW001 Treeway B.V. II Antioxidants; Free radical scavengers Oral AMX0035 Amylyx Pharmaceuticals II Ammonia scavenger; Histone deacetylase inhibitor; Phosphotransferase inhibitor Oral CM383 KeyMed Biosciences I Amyloid beta-protein inhibitors Intravenous Learn more about the emerging dementia associated with Alzheimer's disease therapies @ Dementia Associated with Alzheimer's Disease Clinical Trials Dementia Associated with Alzheimer's Disease Therapeutics Assessment The dementia associated with Alzheimer's disease pipeline report proffers an integral view of the emerging dementia associated with Alzheimer's disease therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Dementia Associated with Alzheimer's Disease Pipeline Report Coverage : Global : Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Adiponectin stimulants, Interleukin 23 inhibitors, Interleukin 6 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Mitogen-activated protein kinase 3 inhibitors, NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists, Microfilament protein modulators, Sigma-2 receptor antagonists, Amyloid beta-protein inhibitors, TREM2 protein-stimulants, Type 5 cyclic nucleotide phosphodiesterase inhibitors, Ammonia scavengers, Histone deacetylase inhibitors, Phosphotransferase inhibitors : Adiponectin stimulants, Interleukin 23 inhibitors, Interleukin 6 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Mitogen-activated protein kinase 3 inhibitors, NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists, Microfilament protein modulators, Sigma-2 receptor antagonists, Amyloid beta-protein inhibitors, TREM2 protein-stimulants, Type 5 cyclic nucleotide phosphodiesterase inhibitors, Ammonia scavengers, Histone deacetylase inhibitors, Phosphotransferase inhibitors Key Dementia Associated with Alzheimer's Disease Companies : BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Merry Life Biomedical Company, Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others. : BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Merry Life Biomedical Company, Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others. Key Dementia Associated with Alzheimer's Disease Pipeline Therapies: Bezisterim KarXT, CT-1812, TB 006, CM383, ALZ 101, AR1001, CT1812, ABBV-916, ALX-001, E2814, VT301, AMX0035, TML-6, PRX-P4-003, ADP037-ABC, GAL-201, MP-010, NVG 300, PSY-02, EMCBD-1, S-636, ADEL-Y07, TRx0237, Remternetug, Masupirdine, Masitinib, Piromelatine, MK-1167, Siponimod, PRI-002, PMZ-1620, Sargramostim, Bepranemab, Lomecel-B, and others. Dive deep into rich insights for new dementia associated with Alzheimer's disease treatments, visit @ Dementia Associated with Alzheimer's Disease Drugs Table of Contents 1. Dementia Associated with Alzheimer's Disease Pipeline Report Introduction 2. Dementia Associated with Alzheimer's Disease Pipeline Report Executive Summary 3. Dementia Associated with Alzheimer's Disease Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Dementia Associated with Alzheimer's Disease Clinical Trial Therapeutics 6. Dementia Associated with Alzheimer's Disease Pipeline: Late-Stage Products (Pre-registration) 7. Dementia Associated with Alzheimer's Disease Pipeline: Late-Stage Products (Phase III) 8. Dementia Associated with Alzheimer's Disease Pipeline: Mid-Stage Products (Phase II) 9. Dementia Associated with Alzheimer's Disease Pipeline: Early-Stage Products (Phase I) 10. Dementia Associated with Alzheimer's Disease Pipeline Therapeutics Assessment 11. Inactive Products in the Dementia Associated with Alzheimer's Disease Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Dementia Associated with Alzheimer's Disease Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the dementia associated with Alzheimer's disease pipeline therapeutics, reach out @ Dementia Associated with Alzheimer's Disease Therapeutics Related Reports Alzheimer's Disease Epidemiology Alzheimer's Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted Alzheimer's disease epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including BioVie, AB Science, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Syneos Health, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, among others. Agitation in Alzheimer's Disease Market Agitation in Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key agitation in Alzheimer's disease companies, including Eli Lilly and Co, BioVie Inc., AB Science SA, Annovis Bio Inc., Cognition Therapeutics Inc., Coya Therapeutics Inc., Actinogen Medical Limited, AC Immune SA, Biogen Inc., Longeveron Inc., among others. Psychosis in Parkinson's and Alzheimer's Disease Market Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others. Alzheimer's Disease Diagnostic Market Alzheimer's Disease Diagnostic Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Alzheimer's disease diagnostic companies, including F. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN™, FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Malaysian Reserve
10-07-2025
- Health
- Malaysian Reserve
CareONE Concierge Now Accepting Candidates for Alzheimer's Device Study
Study offers patients the opportunity to try an experimental, non-drug therapy for Alzheimer's using an FDA-designated Breakthrough Device ATLANTA, July 10, 2025 /PRNewswire/ — CareONE Concierge has announced the launch of a new research study to evaluate an innovative wearable device aimed at addressing cognitive symptoms associated with Alzheimer's-related dementia. The study will utilize NeuroEM Therapeutics'® TEMT-RF cap, a non-invasive device that has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). Alzheimer's disease is a growing global health crisis, affecting nearly 7 million Americans and is projected to impact nearly 13 million by 2050. Despite decades of research, treatment options remain limited, with most current therapies only addressing symptoms rather than the underlying causes of cognitive decline. NeuroEM Therapeutics is pioneering Transcranial Electromagnetic Treatment using Radio Frequencies (TEMT-RF) as a potentially groundbreaking approach to treating the disease at its root. The lightweight, wearable device delivers electromagnetic waves similar to those produced by cell phone signals from multiple emitters. It is being investigated for its potential to break apart toxic protein oligomers within neurons throughout the brain. These oligomers—clusters of beta-amyloid and tau proteins—are thought to drive the progression of Alzheimer's disease. By disrupting these harmful accumulations, TEMT-RF may help restore neuronal function and slow cognitive decline. 'We all know friends and family members who have been impacted by Alzheimer's or dementia,' said Peter Bechtel, CEO of CareONE Concierge. 'This study represents a potential turning point in the fight against these devastating conditions. By participating in this study, individuals have the opportunity to experience cutting-edge, non-drug therapy while contributing to groundbreaking advancements in Alzheimer's treatment.' This study is independently conducted by CareONE Concierge and is designed for individuals with mild to moderate Alzheimer's-related dementia. Participants will be required to wear the device twice daily for one hour, follow a structured research protocol, and complete cognitive assessments throughout the study. Dr. Edward Goodwin, Chief Scientist at NeuroEM, emphasized the scientific foundation behind TEMT-RF, stating, 'Our research has shown that TEMT-RF has the potential to impact the key biological processes associated with Alzheimer's disease. This study will help us gather more real-world data on how the device affects cognitive function and overall brain health.' 'NeuroEM is excited to partner with CareONE Concierge,' stated Chuck Papageorgiou, CEO of NeuroEM Therapeutics. 'Our objective is to promote safe, effective, and non-invasive technologies for cognitive health, and research initiatives like this are essential in helping us uncover the full potential of TEMT-RF. With Alzheimer's cases increasing, innovative research such as this provides new hope for patients, caregivers, and the future of cognitive health. Together, we can take meaningful steps toward a future where memory loss is no longer an inevitable part of aging.' CareONE Concierge is now accepting qualified participants for the study. For more information or to apply, please email CT@ or apply at About CareONE ConciergeCareONE Concierge is committed to delivering Preventative Healthcare solutions that meet the needs of patients, providers, and the healthcare system. The company works with physicians, patients, and healthcare systems to develop turnkey solutions that increase patient outcomes while enhancing revenue and quality metrics. To learn more, visit . About NeuroEM Therapeutics®NeuroEM Therapeutics is leading the way in the development and clinical testing of bioengineered technology to reverse the cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF), the company received the first Breakthrough Device status from the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease. NeuroEM's continued dedication to cutting-edge research is bringing to market a first-in-class wearable device designed for in-home use to extend healthy longevity using patented Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technology. To learn more, visit Media Contact:Wendy Stevens, Study Manager(919) 600-9930wstevens@
